European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets

by Marie Weil
January 14, 2022
A A
Share on LinkedinShare on Twitter

AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialise precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.

The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival. Many transcription factors have long been identified as important targets for new cancer treatments and as drivers of disease,1 but have previously been considered ‘undruggable’ using conventional drug discovery approaches.

To overcome the challenges of targeting transcription factors and to reach underserved patient populations, the collaboration will combine Scorpion’s fully integrated discovery platform with AstraZeneca’s leadership in developing and commercialising precision medicines for cancer treatment.

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Unlocking potentially transformative biology is pivotal for delivering the next wave of cancer treatments. Scorpion’s innovative platform is a strong strategic fit as we explore a range of new modalities across our broad drug discovery toolbox with promise to disrupt the activity of these highly-validated cancer targets.”

Axel Hoos, MD, PhD, Chief Executive Officer, Scorpion, said: “We are pleased to enter into this collaboration with AstraZeneca, whose expertise in drug development and commercialisation complements our discovery platform, which leverages cutting-edge advances in cancer biology and medicinal chemistry, including chemical proteomics, structure-based drug design and machine learning. We expect this collaboration will accelerate Scorpion’s efforts to deliver the promise of ‘Precision Oncology 2.0’: optimised, transformational therapies for more patients living with cancer.”  

Under the terms of the collaboration agreement, Scorpion will lead discovery and certain preclinical activities. AstraZeneca has the exclusive option to licence worldwide rights for up to three drug candidates. AstraZeneca would be responsible for development and commercialisation activities worldwide following opt-in, while Scorpion would retain the option to co-develop and co-promote up to two of these programmes in the US under certain conditions, including if AstraZeneca exercises three licence options.

Financial considerations
Scorpion will receive an upfront cash payment of $75m and is eligible to receive additional success-based payments in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits.

In the event Scorpion opts into co-developing and co-promoting a nominated programme, Scorpion will participate in the operating costs and be entitled to a proportionate share of the economics in the US, subject to certain adjustments.

Tags: < Partnership

Related Industries

Health

Dr. Jost Reinhard appointed new head of Investor Relations at Bayer

September 20, 2023
Health

Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio

August 29, 2023
Health

Bayer appoints Dr. Juergen Eckhardt as new Head of Pharmaceuticals Business Development & Licensing / Open Innovation

August 23, 2023
Health

Innovative research for malaria control driven by three collaborating parties: Swiss TPH, BASF and Promega

August 18, 2023
Health

SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities

August 15, 2023
Health

3M completes sale of dental local anesthetic portfolio assets to Pierrel

August 2, 2023

Huawei and Ocean Research and Conservation Association (ORCA) Show How They Go About Protecting Ireland Marine Life

September 15, 2023

...

Bayer appoints Dr. Juergen Eckhardt as new Head of Pharmaceuticals Business Development & Licensing / Open Innovation

August 23, 2023

...

Bayer to invest EUR 220 million in new R&D facility at its Monheim site

September 1, 2023

...

Partnership Forged to Accelerate the Energy Transition: Hitachi Energy and Google Cloud Combine Energy and Digital Expertise to Advance Sustainability Initiatives

August 25, 2023

...

ABB invests in strategic partnership with clean energy start-up to offer end-to-end wind energy portfolio

September 7, 2023

...

Safran and Cuberg announce collaboration agreement on battery systems for advanced electric aviation

September 14, 2023

...

SKF appoints Sophie Arnius as Head of Investor Relations

September 1, 2023

...

REVEL secures €115 million to boost its car subscription business in Spain

September 16, 2023

...

Rio Tinto appoints new Aluminium Chief Executive

September 6, 2023

...

Bosch and Karlsruhe-based measuring technology specialist Palas team up for better air quality

September 22, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist